Cytovance Biologics, a biopharmaceutical contract development and manufacturing organization (CDMO) of mammalian, microbial biologics and gene therapy plasmid DNA (pDNA), has formed a new agreement with Nature Technology Corporation (NTC) for use of NTC’s proprietary HyperGRO manufacturing platform. This announcement is on the heels of Cytovance launching its Keystone Expression System pDNA manufacturing licensing program.   “Our pDNA programs have greatly advanced due, in-part, to our use of NT...